COVID 19 PANDEMIC NATIONAL RAPID GUIDANCE

At the request of the Government of Canada, CRISM is rapidly developing a series of six national guidance documents. Collectively, the six documents address urgent needs of people who use substances, service providers, and decision makers in relation to the COVID‑19 pandemic. The guidance provided in these document is subject to change as new information becomes available and the landscape of the pandemic and public health responses evolve over time. Check this page often for updates and new resources.

Version 1 – May 2020

Version 1 – July 2020

Version 1 – June 2020

Version 1 – May 2020

national-rapid-guidance-document-CRISM

Version 1 – June 2020

cover-national-rapid-guidance-document-CRISM

Version 1 – June 2020

CRISM National Guideline for the Clinical Management of Opioid Use Disorder

The National clinical practice guidelines on the management of opiod use disorders were developed in accordance with the highest international guideline development standards, and was reviewed and developed by over 40 members of the national guideline development committee. The goals of this guideline are to provide an essential resource to healthcare providers in learning how to manage opioid use disorders and to encourage a greater cohesion and standardization of medical practice, with a hope that these recommendations will be adopted and distributed by relevant regulatory and professional bodies across Canada. This guideline includes two companion documents: a clinical guideline and an operational guidance document.

CRISM National Guideline for the Clinical Management of Opioid Use Disorder

CRISM National Injectable Opioid Agonist Treatment Guideline

CRISM developed the first national injectable opioid agonist treatment (iOAT) guideline in the world. This guideline includes two companion documents: a clinical guideline and an operational guidance document.

National Injectable Opioid Agonist Treatment for Opioid Use Disorder Clinical Guideline

National Injectable Opioid Agonist Treatment for Opioid Use Disorder Operational Guidance

Lower-risk Cannabis Use Guidelines (LRCUG)

The Lower-risk Cannabis use guidelines (LRCUG) have received authoritative national endorsements from six leading national medical, public health, and substance use organizations: Canadian Medical Association (CMA), Canadian Public Health Association (CPHA), Council of Chief Medical Officers of Health (in principle) (CCMOH), Canadian Society of Addiction Medicine (CSAM), Canadian Centre on Substance Use and Addiction (CCSA), and Centre for Addiction and Mental Health (CAMH).

Lower-risk Cannabis Use Guidelines: Evidence Brief

Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations

Start typing and press Enter to search